Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Endocrine and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FSHR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FSHR ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin controlled. HEK293 Expressed for native glycosylation. Sequence Verified. |
View FSHR Products |
| Gene Delivery | FSHR Promise-ORF / Lentivirus Full-length human FSHR ORF for stable cell line generation. Ideal for functional GPCR assays. |
View FSHR Products |
| Benchmark Ab | Anti-FSHR Recombinant Antibody Recombinant positive control derived from clinical/benchmark sequences. |
View FSHR Products |
| Validator | FSHR siRNA Set Target-specific knockdown verification in functional assays. |
View FSHR Products |
| Related Target A | LHCGR Luteinizing Hormone/Choriogonadotropin Receptor. Highly homologous GPCR; critical for off-target and selectivity screening. |
View LHCGR Products |
| Related Target B | AMHR2 Anti-Müllerian Hormone Receptor Type 2. Synergistic ovarian target co-expressed in reproductive disorders and select malignancies. |
View AMHR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 7-TM GPCR | Lentivirus-driven stable cell line construction preserves native GPCR tertiary structure and signaling. |
| Selectivity Counter-Screening (LHCGR/TSHR) | High-purity recombinant extracellular domains (ECD) of homologous receptors available for off-target profiling. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reference controls. |
| False Positives in Binding Assays | Sequence-verified siRNA pool included for target knockdown and specificity validation. |
Live FSHR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FSHR therapeutics is intensifying, with major players shifting focus from traditional gonadotropin-based fertility treatments to highly selective oral small molecule allosteric modulators and targeted oncology therapeutics. As first-generation fertility therapies reach maturity, the next wave of R&D is targeting FSHR in extra-gonadal tissues (such as bone osteoclasts and adipose tissue) and tumor neovasculature, opening up new therapeutic paradigms in osteoporosis, obesity, and solid tumor oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric Modulators) | Bayer, Merck KGaA, Organon | Infertility, Assisted Reproductive Technology (ART) | Functional GPCR validation (Need Lentivirus for high-expression stable cell lines to monitor cAMP/Calcium flux) |
| Monoclonal Antibodies (mAbs) | Academic institutions, Specialized Biotechs | Osteoporosis, Obesity, Cancer Cachexia | Epitope mapping & binding kinetics (Need high-purity recombinant FSHR ECD-Fc proteins) |
| ADC / Bispecifics | Oncology-focused Biotechs | Ovarian Cancer, Solid Tumor Neovasculature | Internalization and cytotoxicity assays (Need sequence-verified benchmark antibodies and stable expression models) |